Results 51 to 60 of about 7,117 (221)

Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner

Pharmaceutics, 2022
BTK inhibitor (BTKi) Ibrutinib carries an increased bleeding risk compared to more selective BTKis Acalabrutinib and Zanubrutinib, however, its impact on vascular endothelium remains unknown.
Jia Liu, Zhuojun Liu, Jing Zhang, Xiaofang Chen, Junge Chen, Linlin Sui, Jian Yu   +6 more
doaj   +1 more source

BTK Inhibitors Impair Platelet-Mediated Antifungal Activity [PDF]

, 2022
In recent years, the introduction of new drugs targeting Bruton’s tyrosine kinase (BTK) has allowed dramatic improvement in the prognosis of patients with chronic lymphocytic leukemia (CLL) and other B-cell neoplasms.
Atene C. G., Barozzi P., Castelli I., Comoli P., Fiorcari S., Forghieri F., Lagreca I., Luppi M., Maccaferri M., Maffei R., Manfredini R., Marasca R., Martinelli S., Nasillo V., Paolini A., Potenza L., Riva G., Tagliafico E., Trenti T., Vallerini D.   +19 more
core   +1 more source

2026 Update on the Management of Diffuse Large B‐Cell Lymphoma

American Journal of Hematology, EarlyView.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) is the most common type of NHL in the Western Hemisphere. It comprises a heterogenous group of lymphomas, with different biology and clinical prognoses. R‐CHP remains the backbone of therapy, and frontline therapeutic options in fit patients are pola‐R‐CHP and R‐CHOP, whereas elderly or frail/unfit ...
Elise A. Chong, Emily B. Tomasulo, Stefan K. Barta   +2 more
wiley   +1 more source

Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions

Haematologica, 2019
While efficient at treating B-cell malignancies, Bruton tyrosine kinase (BTK) inhibitors are consistently reported to increase the risk of bleeding. Analyzing platelet aggregation response to collagen in platelet-rich plasma allowed us to identify two ...
Jennifer Series, Cédric Garcia, Marie Levade, Julien Viaud, Pierre Sié, Loïc Ysebaert, Bernard Payrastre   +6 more
doaj   +1 more source

Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor

Current Oncology, 2021
Bruton tyrosine kinase (BTK) inhibitors have become an important therapy for untreated and previously treated patients with chronic lymphocytic leukemia (CLL).
Omar Alkharabsheh, Alhareth Alsayed, Diana M. Morlote, Amitkumar Mehta   +3 more
doaj   +1 more source

How to perform aggregometry and lumi-aggregometry in mouse platelets [PDF]

, 2018
Light transmission aggregometry (LTA) and lumi-aggregometry are the gold standard platelet assays both clinically and for basic research. The availability of different strains of genetically modified mice, and mouse models of human disease means that ...
Craig E. Hughes, Harrison J, Lages B, Levin J, Longmore GD   +4 more
core   +1 more source

Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option [PDF]

, 2023
Ibrutinib, the first-in-class Bruton’s tyrosine kinase inhibitor (BTKi), is a commonly deployed therapeutic option for previously untreated and relapsed/refractory (R/R) patients with chronic lymphocytic leukemia (CLL).
Allsup, David, Molica, Stefano, Polliack, Aaron, Tam, Constantine   +3 more
core   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Cost-effectiveness of acalabrutinib monotherapy or with obinutuzumab versus chemoimmunotherapy for untreated chronic lymphocytic leukemia in China

Therapeutic Advances in Hematology
Background: Acalabrutinib is a highly selective, latest generation Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia (CLL).
Mengya Li, Xiaoyan Zhong, Chengbin Zhang, Hongli Luo, Li Luo, Yilan Huang, Longyang Jiang   +6 more
doaj   +1 more source

Invasive Aspergillosis with impaired neutrophil responses against Aspergillus fumigatus in patients treated with Acalabrutinib—findings from three cases

International Journal of Infectious Diseases
Objectives: Ibrutinib, a first-generation covalent Bruton's tyrosine kinase inhibitor (BTKi) was found to be a risk factor for the occurrence of invasive fungal complications.
Marion Blaize, Guillaume Thizy, Alexandre Boissonnas, Anaïs Portalier, Fanny Lanternier, Clémentine de La Porte des Vaux, Felipe Suarez, Marie-Elisabeth Bougnoux, Juliette Guitard, Arnaud Jabet, Nicolas Stocker, Abdelmalek Aoudjhane, Damien Roos-Weil, Arnaud Fekkar   +13 more
doaj   +1 more source